A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
Document Type
Article
Publication Title
Annals of oncology : official journal of the European Society for Medical Oncology
First Page
1045
Last Page
1046
DOI
10.1016/j.annonc.2021.04.013
Publication Date
8-1-2021
Recommended Citation
Bellone, S; Roque, D M.; Siegel, E R.; Buza, N; Hui, P; Bonazzoli, E; Guglielmi, A; Zammataro, L; Nagarkatti, N; Zaidi, S; Lee, J; Silasi, D-A; Huang, G S.; Andikyan, V; Damast, S; Clark, M; Azodi, M; Schwartz, P E.; Tymon-Rosario, J; Harold, J; Mauricio, D; Zeybek, B; Menderes, G; Altwerger, G; Ratner, E; Alexandrov, L B.; Iwasaki, A; Kong, Y; Song, E; Dong, W; Elvin, J; and Choi, J, "A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)" (2021). Obstetrics and Gynecology. 86.
https://scholar.bridgeporthospital.org/obgyn/86
Identifier
33932502 (pubmed); NIHMS1830326 (mid); PMC9465821 (pmc); 10.1016/j.annonc.2021.04.013 (doi); S0923-7534(21)01170-4 (pii)